JOHNSON & JOHNSON — Director's Dealing 2022

Jan 13, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2022-01-03

Reporting Person: Mammen Mathai (EVP, Pharm, R&D)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	32477.0000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Options (Right to Buy)	$129.5100	2028-02-11	Common Stock (28927.0000)		Direct
Employee Stock Options (Right to Buy)	$131.9400	2029-02-11	Common Stock (36098.0000)		Direct
Employee Stock Options (Right to Buy)	$151.4100	2030-02-10	Common Stock (58130.0000)		Direct
Employee Stock Options (Right to Buy)	$164.6200	2031-02-28	Common Stock (43149.0000)		Direct
Restricted Share Units	$		Common Stock (35951.0000)		Direct
Restricted Share Units	$		Common Stock (3929.0000)		Direct
Restricted Share Units	$		Common Stock (4545.0000)		Direct
Restricted Share Units	$		Common Stock (7418.0000)		Direct

Footnotes

F1: Vested and exercisable on the third anniversary of the date of the grant.

F2: Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock and vests on the third anniversary of the date of grant.